Oxaliplatino Aurovit

Oxaliplatin, the active ingredient in Oxaliplatino Aurovit, is a platinum‑based chemotherapy agent presented as a sterile powder for intravenous infusion use. It treats colorectal cancer in adult patients, typically as part of combination regimens. GNH USA supplies Oxaliplatino Aurovit as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatino Aurovit as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin is a platinum‑based chemotherapy drug that acts on the colorectal cancer treatment pathway.

- Metastatic colorectal cancer: Used in combination with fluoropyrimidine therapy to improve response rates and survival. - Adjuvant colorectal cancer: Administered after surgical resection to reduce the risk of disease recurrence. - Advanced gastrointestinal tumors: Utilized within multi‑drug protocols for disease control in selected cases.

Oxaliplatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting: Frequent episodes during or after infusion. - Peripheral neuropathy: Tingling or numbness in the hands and feet, often dose‑related. - Diarrhea: Loose stools that may require supportive care. - Fatigue: Generalized tiredness affecting daily activities. - Myelosuppression: Reduced blood cell counts, increasing infection risk. - Elevated liver enzymes: Mild, transient rises in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: Anaphylaxis or bronchospasm during infusion. - Acute neurotoxicity: Sudden onset of muscle cramps or jaw tightness. - Thrombotic events: Blood clot formation in veins or arteries. - Severe myelosuppression: Profound neutropenia or thrombocytopenia requiring hospitalization. - Renal impairment: Deterioration of kidney function, especially with pre‑existing disease. - Cardiac arrhythmias: Irregular heart rhythms observed during infusion.

When handling Oxaliplatino Aurovit, clinicians should observe standard oncology safety protocols and monitor patients closely.

- Renal function assessment: Evaluate baseline creatinine and adjust therapy if impairment is present. - Neuropathy monitoring: Conduct regular neurological examinations to detect early signs of peripheral neuropathy. - Hematologic surveillance: Perform routine complete blood counts to identify myelosuppression. - Hepatic function checks: Monitor liver enzymes before each cycle. - Pregnancy and lactation warning: Contraindicated in pregnant or breastfeeding individuals due to fetal toxicity. - Store at ambient temperature: Keep vials in the original packaging, protect from light and moisture.

Oxaliplatin may interact with several concomitant medicines, requiring careful review of the patient’s medication list.

Major Interactions (Avoid): - Nephrotoxic agents: Concurrent use with aminoglycosides or NSAIDs can worsen kidney injury. - Anticoagulants anticoagulation: Increased bleeding risk when combined with warfarin or direct oral anticoagulants.\nModerate  -       ").